GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bolt Biotherapeutics Inc (NAS:BOLT) » Definitions » Return-on-Tangible-Asset

Bolt Biotherapeutics (Bolt Biotherapeutics) Return-on-Tangible-Asset : -28.57% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Bolt Biotherapeutics Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Bolt Biotherapeutics's annualized Net Income for the quarter that ended in Mar. 2024 was $-43.24 Mil. Bolt Biotherapeutics's average total tangible assets for the quarter that ended in Mar. 2024 was $151.34 Mil. Therefore, Bolt Biotherapeutics's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 was -28.57%.

The historical rank and industry rank for Bolt Biotherapeutics's Return-on-Tangible-Asset or its related term are showing as below:

BOLT' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -127.86   Med: -64.1   Max: -32.9
Current: -36.02

During the past 6 years, Bolt Biotherapeutics's highest Return-on-Tangible-Asset was -32.90%. The lowest was -127.86%. And the median was -64.10%.

BOLT's Return-on-Tangible-Asset is ranked better than
52.26% of 1552 companies
in the Biotechnology industry
Industry Median: -39.47 vs BOLT: -36.02

Bolt Biotherapeutics Return-on-Tangible-Asset Historical Data

The historical data trend for Bolt Biotherapeutics's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bolt Biotherapeutics Return-on-Tangible-Asset Chart

Bolt Biotherapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial -94.65 -127.86 -55.66 -32.90 -35.71

Bolt Biotherapeutics Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -31.30 -36.40 -35.53 -42.74 -28.57

Competitive Comparison of Bolt Biotherapeutics's Return-on-Tangible-Asset

For the Biotechnology subindustry, Bolt Biotherapeutics's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bolt Biotherapeutics's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bolt Biotherapeutics's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Bolt Biotherapeutics's Return-on-Tangible-Asset falls into.



Bolt Biotherapeutics Return-on-Tangible-Asset Calculation

Bolt Biotherapeutics's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-69.197/( (227.807+159.784)/ 2 )
=-69.197/193.7955
=-35.71 %

Bolt Biotherapeutics's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-43.244/( (159.784+142.892)/ 2 )
=-43.244/151.338
=-28.57 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2024) net income data.


Bolt Biotherapeutics  (NAS:BOLT) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Bolt Biotherapeutics Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Bolt Biotherapeutics's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Bolt Biotherapeutics (Bolt Biotherapeutics) Business Description

Traded in Other Exchanges
Address
900 Chesapeake Drive, Redwood, CA, USA, 94063
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems.
Executives
William P. Quinn officer: Chief Financial Officer SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BOULEVARD, SUITE 400, SOUTH SAN FRANCISCO CA 94080
Edgar Engleman director 575 HIGH STREET, STE 201, PALO ALTO CA 94301
Vivo Capital Fund Viii, L.p. 10 percent owner 505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301
Laura Berner director C/O BOLT BIOTHERAPEUTICS, INC., 900 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Novo Holdings A/s 10 percent owner TUBORG HAVNEVEJ 19, HELLERUP G7 2900
James Healy director 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025
Brian O'callaghan director 550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Frank D. Lee director C/O FORMA THERAPEUTICS HOLDINGS, INC., 500 ARSENAL STREET, SUITE 100, WATERTOWN MA 02472
Kathleen Laporte director
Miller Richard A Md director PHARMACYCLICS INC, 995 E ARQUES AVE, SUNNYVALE CA 94085-4521
Mahendra Shah director 2250 HOLCOMBE BLVD, HOUSTON TX 77030
Grant Yonehiro officer: Chief Business Officer C/O MAXYGEN, INC., 515 GALVESTON DRIVE, REDWOOD CITY CA 94063
Randall C Schatzman director, officer: Chief Executive Officer 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
David Dornan officer: Chief Scientific Officer C/O BOLT BIOTHERAPEUTICS, INC., 640 GALVESTON DRIVE, REDWOOD CITY CA 94063
Edith A. Perez officer: Chief Medical Officer C/O BOLT BIOTHERAPEUTICS, INC., 640 GALVESTONE DRIVE, REDWOOD CITY CA 94063

Bolt Biotherapeutics (Bolt Biotherapeutics) Headlines

From GuruFocus

Bolt Biotherapeutics to Present at February Investor Conferences

By Stock market mentor Stock market mentor 02-01-2023

Bolt Biotherapeutics to Present at Stifel 2022 Healthcare Conference

By Value_Insider Value_Insider 11-01-2022